**Table A3. Multivariate analysis according to different inflammatory and nutritious index in patients with PD-L1 <1% (n=42)**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Different variables | | Progression-free survival | | | | | Overall survival | | | | |
| NLR |  | Age | Gender | PS | Histology | NLR | Age | Gender | PS | Histology | NLR |
| HR | 1.081 | 1.197 | 1.525 | 0.911 | 1.446 | 0.960 | 1.138 | 1.890 | 0.886 | 1.935 |
| 95% CI | 0.717-1.620 | 0.690-1.973 | 0.861-2.680 | 0.606-1.382 | 0.930-2.338 | 0.579-1.589 | 0.605-2.142 | 0.996-3.586 | 0.427-1.253 | 0.962-3.893 |
| *p*-value | 0.704 | 0.501 | 0.144 | 0.658 | 0.102 | 0.874 | 0.690 | 0.051 | 0.252 | **0.043** |
| PLR |  | Age | Gender | PS | Histology | PLR | Age | Gender | PS | Histology | PLR |
| HR | 1.121 | 1.128 | 1.569 | 0.956 | 1.409 | 0.984 | 0.953 | 1.966 | 0.787 | 1.664 |
| 95% CI | 0.748-1.677 | 0.633-1.910 | 0.905-2.704 | 0.647-1.426 | 0.949-2.094 | 0.590-1.621 | 0.473-1.904 | 1.075-3.693 | 0.482-1.292 | 1.011-2.850 |
| *p*-value | 0.573 | 0.667 | 0.106 | 0.823 | 0.088 | 0.951 | 0.962 | **0.028** | 0.339 | **0.044** |
| SII |  | Age | Gender | PS | Histology | SII | Age | Gender | PS | Histology | SII |
| HR | 1.063 | 1.339 | 1.467 | 1.010 | 1.459 | 0.947 | 1.316 | 1.954 | 0.879 | 1.651 |
| 95% CI | 0.708-1.589 | 0.767-2.206 | 0.823-2.639 | 0.692-1.497 | 0.920-2.275 | 0.571-1.571 | 0.689-2.513 | 1.026-3.719 | 0.550-1.403 | 0.898-3.034 |
| *p*-value | 0.762 | 0.287 | 0.190 | 0.956 | 0.105 | 0.833 | 0.417 | **0.038** | 0.591 | 0.107 |
| PNI |  | Age | Gender | PS | Histology | PNI | Age | Gender | PS | Histology | PNI |
| HR | 1.026 | 1.585 | 1.406 | 0.975 | 0.584 | 0.855 | 2.774 | 1.636 | 0.808 | 0.233 |
| 95% CI | 0.670-1.563 | 0.855-2.951 | 0.793-2.481 | 0.663-1.453 | 0.339-0.961 | 0.493-1.460 | 1.073-8.081 | 0.887-3.050 | 0.491-1.337 | 0.081-0.554 |
| *p*-value | 0.904 | 0.139 | 0.238 | 0.901 | **0.034** | 0.569 | **0.034** | 0.113 | 0.402 | **<0.001** |
| ALI |  | Age | Gender | PS | Histology | ALI | Age | Gender | PS | Histology | ALI |
| HR | 1.060 | 1.078 | 1.617 | 0.979 | 0.745 | 0.930 | 0.898 | 1.948 | 0.825 | 0.484 |
| 95% CI | 0.694-1.610 | 0.593-1.883 | 0.910-2.854 | 0.664-1.461 | 0.432-1.213 | 0.545-1.553 | 0.428-1.766 | 1.038-3.707 | 0.507-1.351 | 0.184-0.987 |
| *p*-value | 0.783 | 0.796 | 0.099 | 0.916 | 0.243 | 0.783 | 0.762 | **0.037** | 0.440 | **0.045** |
| GPS |  | Age | Gender | PS | Histology | GPS | Age | Gender | PS | Histology | GPS |
| HR | 1.112 | 1.487 | 1.452 | 1.048 | 1.577 | 0.998 | 1.560 | 1.885 | 0.923 | 1.925 |
| 95% CI | 0.736-1.676 | 0.827-2.556 | 0.827-2.556 | 0.715-1.561 | 0.974-2.552 | 0.974-1.660 | 0.723-3.416 | 1.022-3.589 | 0.575-1.503 | 1.001-3.932 |
| *p*-value | 0.608 | 0.186 | 0.190 | 0.809 | 0.063 | 0.995 | 0.248 | **0.042** | 0.742 | **0.049** |

Abbreviations: PS, performance status; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; SII, systemic immune inflammation index; PNI, prognostic nutrition index; ALI, advanced lung cancer inflammation index; GPS, Glasgow prognostic score; HR, hazard ratio; 95% CI, 95% confidence interval; PD-L1, programmed death ligand-1.